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Hepatitis C virus (HCV) infection is a relevant clinical and
public health problem. The virus infects approximately 3% of
the global population, and is one of the leading causes of
end-stage liver diseases and hepatocellular carcinoma, causing
>350 000 deaths yearly [1].
Unlike from other agents causing chronic infections (e.g.
human immunodeﬁciency virus and hepatitis B virus), HCV
cannot establish a permanent intracellular genomic archive,
and its persistence relies on continuous replication. Hence,
HCV can, theoretically, be eradicated from the host, provided
that new replication cycles are prevented [2].
For >20 years, the combination of pegylated interferon
(Peg-IFN) and ribavirin was the pillar of anti-HCV therapy,
often being referred to as the standard of care (SOC).
However, the success rate of the SOC is only approximately
50% overall. Furthermore, patients in whom there is a failure
to clear HCV with SOC have little (if any) chance of
subsequent treatment with the same combination being
successful, and, perhaps more importantly, patients with
comorbidities are ineligible to receive Peg-IFN at all [2].
Recently, compounds with direct antiviral activity (DAAs)
have been discovered. The ﬁrst-generation protease inhibitors
(PIs) telaprevir and boceprevir were approved by the FDA on
May 2011 for HCV genotype 1 in combination with the SOC.
These combinations signiﬁcantly improved viral clearance, but
with a signiﬁcant increase in adverse events. Moreover, the
issue of subjects ineligible to receive Peg-IFN remained
unsolved [3,4].
Subsequently, two new drugs, sofosbuvir (NS5B polymerase
inhibitor) and simeprevir (second-generation PI), have been
approved. Many other compounds, with different viral targets,
will enter clinical practice soon, including three NS5A inhib-
itors (ledipasvir, daclatasvir, and ombitasvir), two-second
generation PIs (asunaprevir and ABT-450), and one NS5B
inhibitor (dasabuvir). Combinations of these compounds
promise all-oral, once-daily, ultra-short (8–12 weeks), inter-
feron-free treatment with outstanding efﬁcacy, an improved
safety proﬁle, and no comorbidity contraindications. It is
common opinion that, owing to these new options, HCV will
not represent a signiﬁcant health issue in the near future [3–5].
However, this optimism hides several critical issues. Among
them are: prohibitive cost of the therapy; the best drug
combination(s); when to start treatment and how long to
treat; and transmission by asymptomatic carriers.
Furthermore, it is our ﬁrm opinion that another topical
issue that is not sufﬁciently addressed by current guidelines is
therapeutic response monitoring, which is focused on the
measurement of HCV RNA in the blood, and is aimed at
optimizing therapy duration, to prompt early discontinuation
to prevent potential side effects, and to reduce unnecessary
costs.
Currently, it is assumed that the best chance of HCV
eradication in a patient occurs when viral replication has been
halted for a sufﬁcient time to allow its disappearance from
every infected cell. However, even in cases when HCV RNA is
not detected with the most sensitive assay, it is still possible
that minute, undetected amounts of virus are present.
Previous experience with the SOC has indicated that assays
with higher sensitivity perform better in predicting sustained
virological response in patients who have reached the end of
therapy response. In this respect, the diagnostic armamentar-
ium for monitoring HCV therapy has improved greatly, and the
sensitivity of current real-time PCR-based assays has substan-
tially improved as compared with the ﬁrst-generation assays. It
is not clear whether the sensitivity of current assays could be
further improved, and whether such improvements would
offer any advantage in monitoring DAA-based therapy.
There is a general consensus that the rate of decay of HCV
RNA is predictive of response. Clear stopping rules have been
established for the SOC, to allow treatment duration to be
adapted on the basis of early decay of viral load, and even for
treatment to be stopped in cases of insufﬁcient or absent
decline. However, for the DAA-containing regimens, therapy
tailoring indications and stopping rules have been formulated
for a very limited number of compounds; in addition, there is a
great degree of variability in the cut-off levels to adopt, even
for DAAs with similar mechanisms of action and administra-
tion schedules. In fact, negative and positive predictive values
of different cut-off levels have been established with respect to
different endpoints and criteria, so that a uniform decision
pathway is lacking [3].
Another highly debated issue in monitoring strategies is
resistance to antivirals. Owing to the high replication rate of
HCV, and to the lack of proofreading activity of viral
polymerase, HCV is highly variable, and each possible muta-
tion, and even each combination of mutations, arises every day
within each infected individual, representing the basis for
selection of resistant variants by DAAs [6]. Despite reduced
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ﬁtness, such variants rapidly overgrow wild-type viruses, often
favoured by the accumulation of additional, ﬁtness-restoring,
mutations [7]. Actually, natural variants carrying resis-
tance-associated mutations have been widely described in
both conventional and next-generation sequencing-based
studies, and have been shown to rapidly accumulate through-
out the course of DAA treatment, if viral replication is not
completely suppressed [8,9]. However, there is no agreement
on the usefulness of performing resistance testing prior to the
initiation of DAA-based therapy; even the use of resistance
testing in failing cases is questioned, for a number of reasons. In
fact, not all virological failures are accounted for by the
emergence of resistant variants; the resistant variants rapidly
decline (although they do not always disappear) after treat-
ment is stopped; and the availability of different classes of
drugs, and their combined use, may achieve an enormous
increase in the genetic barrier to antiviral resistance, over-
coming this problem.
In conclusion, the main ﬁrm point is that the new
interferon-free combinations will be much more effective
and less toxic than previous regimens. However, the upcoming
treatment revolution will pose signiﬁcant clinical challenges.
The recent history of HCV therapy was dominated by
punctual, well-settled and widely accepted guidelines that
provided clinicians with detailed indications on who to treat,
and for how long and when. In contrast, in the immediate
future, clinicians will face signiﬁcant uncertainties regarding
how to manage their patients. Virologists are requested to face
these challenges by establishing/validating suitable markers and
predictors to assess viral eradication and provide guidance to
clinicians.
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